Max Healthcare Institute Ltd

Max Healthcare Institute Ltd announced an upgrade in its Environmental, Social, and Governance (ESG) ratings by Crisil ESG Ratings & Analytics Limited. The company's ESG Rating has moved from CRISIL ESG 63 to CRISIL ESG 68, falling within the 'Strong' rating category. Concurrently, its Core ESG Rating was upgraded from CRISIL Core ESG 72 to CRISIL Core ESG 76. Crisil assigned these ratings independently based on the company's public disclosures, without any prior engagement with Max Healthcare. This disclosure highlights the company's improved ESG performance and commitment.

Max Healthcare Institute Ltd announced significant changes in its senior management following a board meeting on August 13, 2026. Mr. Ajay Vij has been appointed as Director - Chief Supply Chain & Procurement Officer, effective August 14, 2026. Mr. Pawan Kumar Marella will join as Senior Director - Chief Experience & Brand Officer, starting August 17, 2026. Concurrently, Dr. N. Venkatesan, Senior Director & Chief Procurement Officer, will resign effective August 31, 2026. The board also approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and a capital expenditure of approximately ₹425 Crore for the expansion of Max Super Speciality Hospital, Vaishali. Additionally, the company received in-principle approval to explore setting up medical colleges/institutions and amend its Memorandum of Association.

Max Healthcare Institute Ltd. reported a 16% year-on-year growth in gross revenue for the first quarter ended June 30, 2026, reaching ₹2,982 Cr. Network Operating EBITDA increased by 15% YoY to ₹704 Cr, with an EBITDA margin of 24.8%. Profit After Tax (PAT) stood at ₹357 Cr, a 3% YoY increase. Key drivers included a 10% YoY rise in Occupied Bed Days (OBDs) and a 5% YoY increase in Average Revenue Per Operating Bed (ARPOB). The company also announced strategic acquisitions, including a controlling stake in Kalinga Hospital Limited and full ownership of Yerawada Properties Private Limited, alongside board approval for a brownfield expansion and in-principle approval for medical education ventures. Max Lab and Max@Home also showed significant revenue growth.

Max Healthcare Institute Ltd. reported a strong first quarter for FY27, with gross revenue reaching ₹2,982 Cr, a 16% year-over-year increase. Network Operating EBITDA also saw a significant rise of 15% YoY to ₹704 Cr. Profit After Tax (PAT) stood at ₹357 Cr. The company highlighted growth driven by increased Occupied Bed Days (OBDs) and international patient revenue, which grew 18% YoY. Key strategic moves during the quarter included the acquisition of a controlling stake in Kalinga Hospital Limited and full ownership of Yerawada Properties Private Limited, paving the way for a new hospital in Pune. The company also approved capital expenditure for a brownfield expansion and is exploring entry into medical education.

Max Healthcare Institute Ltd announced the approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also sanctioned a capital expenditure of approximately ₹425 Crore for the expansion of Max Super Speciality Hospital, Vaishali, by constructing an additional block. Furthermore, the company received in-principle approval to explore setting up medical colleges/institutions, subject to regulatory changes and member approval. Key management appointments were also approved, including Mr. Ajay Vij as Director - Chief Supply Chain & Procurement Officer and Mr. Pawan Kumar Marella as Senior Director - Chief Experience & Brand Officer. Dr. N. Venkatesan resigned as Senior Director & Chief Procurement Officer.

Max Healthcare's consolidated revenue for Q1 FY27 (quarter ended June 30, 2026) rose 16.7% YoY and 10.4% QoQ to ₹2,366 Cr (₹2,407 Cr total income), while consolidated PAT (profit for the period) grew a much slower 4.9% YoY and fell 5.6% QoQ to ₹322.96 Cr — of which ₹322.49 Cr accrued to owners after a newly-arisen ₹0.47 Cr minority interest tied to the Kalinga Hospital acquisition. Basic EPS was ₹3.32, against ₹3.17 a year ago and ₹3.52 in the prior quarter. No reliable street/consensus estimate for this specific print could be confirmed via search, so vs-street is left unassessed rather than guessed. The gap between revenue and profit growth is a margin story: OPM (EBITDA margin) slipped to 25.3% from 25.8% YoY and from 28.3% QoQ, and NPM fell to 13.4% from 14.9% YoY and 15.6% QoQ. Finance costs rose 29% YoY to ₹71.0 Cr and depreciation rose 26% YoY to ₹131.7 Cr, both inflated by the ECB drawn to fund the ₹298 Cr Kalinga Hospital acquisition (58.28% stake, consolidated from May 18, 2026) and ongoing capacity build-out. This lines up with management's prior-quarter guidance, which explicitly flagged near-term EBITDA drag from newly commissioned/acquired capacity before full operating leverage shows up as occupancy ramps — so the margin dip looks like guided-for integration cost, not a surprise miss against what management said. Standalone (parent-only) numbers show a starker divergence: standalone PAT was nearly flat YoY at ₹167.6 Cr (+0.9%) on revenue of ₹782.9 Cr (+12.8% YoY), confirming most of the consolidated growth is coming from subsidiaries and newly consolidated hospitals rather than the core standalone entity. Network-wide capacity utilisation was above 75% in the quarter on an existing base of 6,100+ beds. The same board meeting approved ₹425 Cr of capex for a new 'Tower 3' block (~250 beds) at Max Super Speciality Hospital, Vaishali, commissioning by November 2029, plus an in-principle approval to explore setting up medical colleges. There were no exceptional items this quarter on either basis, unlike FY26's full year, which carried ₹48.2 Cr of labour-code and merger stamp-duty exceptional charges — so this YoY comparison is clean on both sides. No separate management press release accompanies this filing beyond the board-outcome letter, so there is no additional management framing to reconcile against the numbers. Going into Q2 FY27, the markers to watch are whether OPM recovers toward the 28%+ level seen in Q4 FY26 as the Kalinga integration matures and occupancy ramps, and how finance costs trend now that an ECB has been drawn for the acquisition.

Max Healthcare Institute Ltd announced the grant of 3,61,827 stock options to eligible employees under its Employee Stock Option Scheme 2022. The Nomination and Remuneration Committee (NRC) approved the grant on August 13, 2026. The options are split into two tranches: 1,61,827 options at an exercise price of ₹800 per option and 2,00,000 options at ₹350 per option. These options are convertible into equity shares with a face value of ₹10 each. Vesting is subject to pre-vesting conditions and occurs between 1 to 5 years from the grant date, with an exercise window of 3 years post-vesting. The scheme is administered by the NRC.

Max Healthcare Institute Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda item for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Additionally, the company confirmed that the trading window for its securities will remain closed for designated persons and their immediate relatives until 48 hours after the declaration of these financial results. This disclosure will also be available on the company's official website.

Max Healthcare Institute Ltd held its 25th Annual General Meeting (AGM) on July 30, 2026, via video conference. The meeting commenced at 10:30 am IST and concluded at 11:44 am IST. A total of 160 members, including representatives, were present. The AGM was conducted in compliance with the Companies Act, 2013, and SEBI regulations, with a webcast facility provided for members. The registered office was considered the deemed venue. The notice of the AGM and the Integrated Annual Report for FY 2025-26 were shared with members.

Max Healthcare Institute Ltd conducted its 25th Annual General Meeting (AGM) on July 30, 2026, via video conference. The meeting, held in accordance with the Companies Act, 2013, and SEBI regulations, was accessible to members through a webcast facility. Electronic copies of the AGM Notice and Integrated Annual Report for FY 2025-26 were distributed to registered members. The company confirmed the presence of the requisite quorum and introduced the Board of Directors and key management personnel attending the meeting from various locations. Representatives from statutory, secretarial, and cost auditors were also present, along with a scrutinizer appointed for the e-voting process.